
==== Front
Eur Arch Otorhinolaryngol
Eur Arch Otorhinolaryngol
European Archives of Oto-Rhino-Laryngology
0937-4477
1434-4726
Springer Berlin Heidelberg Berlin/Heidelberg

39014252
8824
10.1007/s00405-024-08824-5
Laryngology
Platelet Rich plasma injection of the vocal folds in benign vocal pathologies
Mackay Georgia
http://orcid.org/0000-0002-3302-7045
Allen Jacqui jeallen@voiceandswallow.co.nz

https://ror.org/03b94tp07 grid.9654.e 0000 0004 0372 3343 Department of Surgery, University of Auckland, Private Bag 91019, Grafton Auckland, New Zealand
17 7 2024
17 7 2024
2024
281 10 54195428
2 6 2024
1 7 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Purpose

There are few options for treatment of dysphonia secondary to vocal pathology related to lamina propria scar, atrophy, sulcus, or inflammatory disorders. Platelet rich plasma (PRP) may provide anti-inflammatory and regenerative properties seen with other tissue engineering therapies without the risks associated with these treatments. We evaluated vocal fold (VF) injection of PRP for feasibility, phonatory effects, patient satisfaction and durability.

Methods

Patients with dysphonia secondary to vocal fold scar, atrophy, sulcus and inflammatory lesions were included. PRP injections were administered in office, to bilateral vocal folds. Patients were followed up at 1 week, 1 month, 3 months and 6 months to assess outcomes (GRBAS scale, maximum phonation time, vocal fatigue index (VFI), voice handicap index (VHI-10) and stroboscopy).

Results

75 intracordal PRP injections were administered to 48 patients. All injections were completed, and no adverse reactions were experienced. Improvements in VHI-10 scores at 1,3,6 months were seen (mean VHI 21.73 at baseline, 15.62 at six months, p < 0.001). 72.3% rated improvement at 7 or above on Likert scale. 95.7% of patients would consider a future PRP injection. Secondary outcomes VFI, MPT, and GRBAS also demonstrated significant improvements over time. Patients receiving a single PRP injection (n = 26) still demonstrated significant VHI-10 improvements at 1,3 and 6 months.

Conclusions

VF office PRP injections are feasible and safe and can provide phonatory benefit and reduce vocal effort in benign VF disorders. A single PRP injection is sufficient to provide sustained benefit in some cases.

Level of evidence

Level III: prospective cohort study.

Keywords

Platelet rich plasma
Dysphonia
Vocal fold
Scarring
Atrophy
Sulcus
University of AucklandOpen Access funding enabled and organized by CAUL and its Member Institutions

issue-copyright-statement© Springer-Verlag GmbH Germany, part of Springer Nature 2024
==== Body
pmcIntroduction

The intricate microcellular environment of the vocal fold (VF) is intimately related to vocal function [1]. Precise ratios of collagen, elastin, and hyaluronic acid within the superficial lamina propria (SLP) of the VF contribute the viscoelastic and strength properties that allow for VF oscillation and sound production [2–4]. Unlike the skin, where scars and defects merely appear unsightly, scarring of the VF significantly impairs vocal function [5, 6]. Even small disruptions to the unique architecture of the VF can cause significant dysphonia, due to impairments of wave oscillation, or VF free edge irregularities hindering full glottic contact. VF scar, sulcus and atrophy sit along a spectrum of disorders affecting the LP of the vocal fold [7–11]. Whilst their aetiologies and pathogenesis differ, they share similar features of inflammatory change, collagen dysregulation, and loss of the glycosaminoglycans and hyaluronic acid [2, 12, 13]. Unlike VF paralysis (where medialisation of the affected VF into the airflow stream can allow for normal glottic contact and VF oscillation), using medialisation techniques for VF scar, sulcus and atrophy yield underwhelming results, as glottic insufficiency is only one element of the problem [14]. Similarly, the placement of exogenous substrates into the VF can result in poor vocal outcomes due to differing vibratory properties of manufactured substances and substance mass compared to native VF SLP components [15, 16].

Research into biological techniques have gained popularity in laryngology for their proposed ability to stimulate regeneration of the lamina propria. The current biologics are in various stages of in vitro, animal and human testing, and include recombinant growth factors (bFGF and HGF) [12, 13], and stem cell treatments derived from bone marrow and adipose tissue [17–19]. Whilst promising results have been shown in support of the regenerative properties of these techniques, they are resource intensive, expensive, and the ethical and regulatory protocols surrounding this field frequently hinder their progression to widespread human application [6].

Platelet rich plasma (PRP) whilst new in laryngology, is a common treatment option in many fields of medicine, including rheumatology, appearance medicine and plastic surgery [20–23]. Like growth factors and stem cells treatments, PRP is hypothesised to stimulate healing processes in tissues with low healing potentials, and reverse fibrotic processes [24–26]. The growth factors, cytokines and anti-inflammatory properties of PRP provide the theoretical basis for its use in the VFs (PDGF, VEGF, HGF, bFGF) [27–31]. PRP has been shown to reduce NF-kB mediated inflammation [26, 27, 29], and reduce expression of COX-1, COX-2 inflammatory mediators [30]. PRP has been shown to revert TGF-b1 mediated fibrotic and inflammatory signalling pathways [24, 28]. Many methods of PRP preparation exist, and in general they are quick, cost-effective and require minimal training [32–34]. Unlike expensive implants and current commercially-manufactured injection substrates, the cost of PRP is small, limited to standard blood draw equipment, use of a centrifuge machine, which can be found in most centres with lab facilities. There is no direct implant cost as the PRP comes from the patient. Animal and human studies of PRP injections into the VF have confirmed its safety, with no reports of inflammatory reactions, scarring, granulomas or other significant adverse outcomes [31, 35–42]. Current human studies of the use of PRP in the VFs, show improvement in phonatory outcomes out to 1 year after PRP injections, with small cohort sizes and variable follow up duration, meaning further assessment is needed to guide regular office-based use [38, 39, 42].

This study aims to evaluate safety and phonatory outcomes of intracordal PRP injection for benign VF pathology.

Materials and methods

Ethical consent was obtained for this study from the Health and Disability Committee of New Zealand (HDEC Central committee: 2022 FULL 13,929). Patients were treated with bilateral intracordal PRP injections in all cases.

Inclusion and exclusion criteria

Patients were included if they were over 18 years old and reported dysphonia secondary to benign VF disease including: VF scar, atrophy, sulcus and inflammatory lesions. Patients were excluded if a progressive neurological condition was the cause of their dysphonia, malignancy involved the larynx, or they demonstrated clotting disorders or were pregnant. Alternative treatments were offered to patients, and they were given time to consider consenting to PRP injections. Patients with voice change of all severity levels were included, and patients who had received prior treatment with other modalities were eligible for inclusion. As the study aim was to assess safety, tolerance and patient-reported voice benefits, we included individuals with different aetiologies of voice change. This study was not blinded or randomized. All participants received PRP injection.

PRP preparation

Two 8.5 ml samples of blood were drawn into acid citrate dextrose (ACD) vacutainers [Capes Medical, Mangere, New Zealand] via standard phlebotomy technique from the antecubital fossa (ACF) or dorsum of the hand for each patient. Blood samples were centrifuged at 3500-4000 rpm (2030RCF) for 10 min using a Frontier™ 5000 Series Multi-Pro OHAUS centrifuge (FC5714). After centrifugation, the top 2/3 of plasma from each sample was discarded using a 10 ml syringe with a blunt 18-gauge needle. The remaining 1/3 of plasma above the buffy coat (the PRP supernatant) was extracted with a 1 ml syringe, with careful precision so as not to include any red blood cells in the sample.

PRP injection

Patients received PRP injections via transnasal or transcervical (endoscope-guided thyrohyoid approach) standard techniques under local anaesthetic in the office, into the superficial lamina propria. All patients were given bilateral PRP injections regardless of unilateral or bilateral pathology. VFs were over injected until grossly volumized (usually with a yellow coloration), or until spontaneous supernatant extrusion occurred, typically between 0.25 and 0.8 ml each side.

Patients were monitored after injections for 15 min for immediate reactions. Patients were recommended 24 h of voice rest immediately following the procedure to ensure maximal absorption of PRP.

Assessment of voice outcomes

At initial appointment patients completed voice handicap index (VHI-10) and vocal fatigue index (VFI) tools and then during videostroboscopic assessment, performed a range of voiced tasks including range, maximum phonation time (MPT) and whisper speech. The clinician rated the voice using GRBAS scale (grade, roughness, breathiness, asthenia, strain) and estimated mucosal wave amplitude and glottal closure (complete vs. incomplete). All evaluations were performed at each follow up appointment (1, 3, 6 and 12 months) after injection, alongside stroboscopy. Stroboscopy assessment included visualisation of mucosal wave form, glottic contact, phase symmetry and amplitude excursion. Furthermore, at post-injection appointments, patients were asked to rate on a Likert scale (1–10) their willingness to undergo future PRP injections, and their perceived degree of voice improvement.

Statistical tests

Paired t-tests were used to compare pre-injection and post-injection outcomes for parametric data, and Wilcoxon Signed Rank test for non-parametric data. Independent t-tests were used to compare degree of VHI-10 improvement by pathology. Pearson’s correlations were used to compare degree of VHI-10 improvement and age. P value of < 0.05 was considered significant. All statistical tests were performed using SPSS 23 (SPSS, IBM, USA).

Results

A total of 75 intracordal PRP injections were administered to 48 patients over the one-year study period. There were 28 patients with VF atrophy (58.3%), 10 with sulcus or scar (20.8%), and 10 with inflammatory VF disease (20.8%). The study group consisted of 16 males (33.3%), and 32 females (66.7%), with an ethnicity distribution of 38 (79.2%), 3 (6.3%), 3 (6.3%) and 1 (2.1%) for New Zealand European, Asian, Māori and other respectively, 3 patients (6.3%) did not report ethnicity. The ages ranged from 18 to 82 years, median 62 years old (mean 56 years, standard deviation 18.1). 21/48 patients had received previous VF procedures including injection laryngoplasty, Gore-tex™ implants and laser treatment but not within the preceding six months prior to PRP injection. No patient withdrew from the study; however one moved overseas and was lost to follow up, and two patients were excluded from further follow up after receiving other vocal fold procedures. 47 patients had available follow up data at the completion of the study. 26 (54%) patients underwent a single injection, and 22 (46%) patients received 2 or more injections.

Twenty-six patients (54.2%) were professional voice users. The most common voice presenting symptom reported was reduced volume in 23 patients (47.9%), followed by vocal fatigue (12 patients, 25.0%), poor sound quality (9 patients, 18.8%) and odynophonia (4 patients, 8.3%). Mean duration of vocal symptoms was 4.2 years (standard deviation 4.3), (range 0.5–25 years).

All patients received bilateral injections. Average injectate volume on each side was 0.38 ml (standard deviation 0.09, range 0.1-0.7 ml). 43 injections (57.3%) were administered via a transcervical route, and 32 injections (42.7%) by transnasal approach.

Safety

No patient had any significant adverse reaction to PRP injection. The procedure was generally well tolerated with mild discomfort for up to 48 h after injection reported by 17/46 participants (37.0%).

Patient reports

Participants were asked to rate degree of symptom improvement and their willingness to undergo a future PRP injection on a Likert scale from 1 to 10. Forty seven patients had Likert data available, 72.3% (34/47 of patients) rated their improvement at 7 or greater on the Likert scale during follow up. 45/47 (95.7%) reported they would consider having a future PRP injection at their last follow up (≥5 Likert rating). Two participants expressed reluctance towards future injections after experiencing procedural discomfort during the injection, but would consider if performed under a general anaesthetic (Figs. 1 and 2).

Fig. 1 Likert scale (1–10) measures for question “How likely are you to consider a future PRP injection?” at last patient follow up

Fig. 2 Likert scale (1–10) measures for question “How would you rate your degree of vocal improvement after PRP injection?”

Outcomes

Table 1 displays the pair-wise comparisons of the primary study outcomes (VHI-10, VFI, MPT) at various follow up time points, with all results compared to baseline values. Figure 3 displays improvements in VHI-10 across time. 32/47 patients (68.1%) achieved the minimum clinically important difference (MCID) of a decrease in VHI-10 equal to or greater than 5 during the follow up period. There was a significant difference between the baseline mean VHI-10 score and the 1-, 3- and 6-month scores.

Table 1 Comparison of mean values for VHI-10, VFI parts 1 and 2 and MPT across study time points

	Baseline	1 month	3 months	6 months	12 months	
VHI-10	21.73 (n = 45)	16.89 (n = 45)*p < 0.001	17.29 (n = 35)*p = 0.006	15.62 (n = 29)*p < 0.001	12.63 (n = 8)

p = 0.115

	
VFI-1	28.05 (n = 41)	22.70 (n = 43)*

p < 0.001

	20.82 (n = 34)*

p < 0.001

	18.46 (n = 26)*p < 0.001	13.50 (n = 6)*

p = 0.004

	
VFI-2	7.53 (n = 43)	6.35 (n = 43)*p = 0.047	4.94 (n = 34)*p = 0.002	4.77 (n = 26)*

p < 0.001

	2.17 (n = 6)

p = 0.16

	
MPT	14.49 (n = 43)	17.67 (n = 43)*

p < 0.001

	16.19 (n = 32)*

p = 0.001

	15.59 (n = 22)

p = 0.101

	20.20 (n = 6)*

p = 0.022

	
* Represents statically significant comparisons (two tailed p value < 0.05) with baseline value

Fig. 3 Mean VHI-10 scores over time. Star represents significant change compared to baseline values on paired t-test. * Represents statically significant comparisons (two tailed p value < 0.05) with baseline value

There were significant improvements in VFI1 scores at all time points, and improvements in VFI2 scores at 1, 3 and 6 months (Table 1). There was no significant improvement in VFI3 at any time point.

Figure 4 display mean GRBAS measurements over time. Paired t-tests yielded significant reduction in scores at all time points for G, R, B, S compared to baseline. Aesthenia ratings showed significant reduction at 3 and 6 months only.

Fig. 4 Mean GRBAS ratings over time. Star represents significant change compared to baseline values on paired t-test. * Represents statically significant comparisons (two tailed p value < 0.05) with baseline value

Subgroup analysis was undertaken of patients who underwent a single injection (n = 26) only. There was significant improvement in mean VHI-10 comparing baseline VHI-10 (19.42) to 1 month (14.73) (p < 0.001) (n = 26), 3 months (14.38) (p = 0.015) (n = 13) and 6 months (10.73) (p = < 0.001) (n = 11), displayed in Fig. 5.

Fig. 5 Mean VHI-10 scores over time for patients with single injections. Star represents significant change compared to baseline values on paired t-test. * Represents statically significant comparisons (two tailed p value < 0.05) with baseline value

There was no significant difference in mean VHI-10 change between groups related to VF pathology or age.

When analysed by aetiology, the atrophy (n = 26) group saw significant VHI-10 improvements at 1 month (mean change VHI-10 5.6 SD 7.7, p = 0.001), 3 months (mean change VHI-10 3.7 SD 7.2 p = 0.035) and 6 months (mean change VHI-10 6.1, SD 6.3, p = 0.002) compared to baseline, and there were also significant improvements for VFI1, and VFI2 at 1,3 and 6 months in the atrophy group. Scar/sulcus patients (n = 10) did not demonstrate significant VHI-10 improvements across any time period. The inflammatory group (n = 10) demonstrated significant VHI-10 improvement at 1 (mean change VHI-10 6.0 SD 8.0 p = 0.042) and 3 months (mean change VHI-10 8.8 SD 3.7 p = 0.002).

Stroboscopy

Changes seen on stroboscopy after PRP injection included improved glottal contact and greater mucosal wave amplitude with smoother free vocal fold margin (Figs. 6 and 7).

Fig. 6 Stroboscopic image montage of representative case. A) pre-PRP injection demonstrating glottic gap throughout glottal cycle, and B) one month after PRP injection demonstrating reduced glottal gap and increased closed phase of glottic cycle

Fig. 7 Stroboscopic image of representative case. A) Maximal closure position prior to PRP injection demonstrating full length glottal gap and B) Maximal closure position 3 months after PRP injection demonstrating complete glottal closure

Participant comments

During interviews participants were asked open ended questions around their voice progression such as “How has your voice been?”. Two particular themes were evident where patients consistently reported change – fatigue and effort improvement, and improved vocal consistency.

The following are an example of direct quotes from patients.

Theme 1: Reduction in degree of fatigue or effort. During follow up meetings 20 patients volunteered that they needed less effort to use their voice, or lower levels of fatigue or strain.

E.g “I can sing for one hour, and then I can still speak to my wife when I get home, which I didn’t used to be able to do”.

Theme 2: Improved vocal consistency. During follow up meetings 18 patients volunteered that their voice was either more reliable, or that they had more trust in, or more consistency with their voice.

E.g “I can get through a whole performance knowing my voice won’t break”.

Discussion

VF pathologies affecting the SLP (VF atrophy, sulcus, scar and inflammatory processes), pose difficulties for treating clinicians [1, 6, 43]. For patient’s reporting symptomatic dysphonia, but who lack pathological changes severe enough to warrant injection of a (temporary) bulking agent via techniques of injection laryngoplasty or Gore-tex™ (permanent) implantation, or for professional voice users for whom pitch alterations related to bulky implants are unpalatable, there has been a lack of alternate therapy available [14, 15, 44]. These patients typically find themselves offered voice therapy and vocal hygiene as their treatment options.

Our study population included a wide variety of dysphonic patients with differing causes for voice change. These range from severe bilateral congenital sulcus, scarring post-squamous cell carcinoma (SCC) resection and radiation, to discreet inflammatory lesions and diffuse chronic laryngitis. Whilst we did treat patients with perceptually severe dysphonia, we also included those with seemingly normal speaking voices, but with symptoms of vocal fatigue after prolonged use, or difficulties in controlling pitch. We were interested to see if PRP could benefit patients at both ends of disease severity and across various pathologies. Previous studies using PRP for benign vocal pathologies have used serial injections in their study protocols. Both Woo [39, 42] and Woerd [38] performed serial injections spaced one month apart, using three and four serial injections respectively. We hypothesised that in some cases only a single injection would be needed for prolonged phonatory benefits and offered participants one initial injection. Serial injections were performed on a patient-by-patient basis depending on response to the first injection. In 26 patients, sustained vocal improvement after a single injection was achieved with no clinical requirement for repeat injections past six months. These participants demonstrated significant improvement in VHI-10 scores at 1,3 and 6 months after injection, compared to baseline. This is the first study to examine single VF PRP injection outcomes in the short and medium term. Whilst further research is needed to assess which patients will see sustained benefits from a single injection, we are encouraged by the potential of a single injection to produce sustained effects. It is possible that patients experiencing repeated VF trauma (i.e. continued phonotrauma, smoking, illness, reflux) may have either greater VF damage or experience ongoing inflammatory mediator presence in the VF and therefore gain short term benefit from an injection or require additional modulation afforded by repeating PRP application [42]. Around half of the participants in this study had received prior surgical treatments for their voice, without achieving satisfactory voice. These treatments included VF injection with hyaluronic acid gels, Gore-tex™ thyroplasty, and laser therapies. PRP injections appeared to assist both closure issues and viscoelastic properties of the SLP, potentially helping voice across more than one realm. Additional study is needed to quantify the degree of benefit in each parameter, and in varying pathologies. These questions pose interesting directions for future research.

Our findings are congruent with other published literature [38, 39, 42], and supports the safety of PRP VF injections, as no significant adverse outcomes occurred during the study period. In our study, office-based PRP injections were well tolerated and 95.7% of patients would consider another injection based upon their experience. Two patients reported discomfort that would preclude them considering office-based treatment, but still noted improvement in phonation and would accept further PRP if under general anaesthesia.

We were able to identify statistical and clinical improvements in a wide range of phonatory outcomes across time points: MPT, VFI, VHI-10 and GRBAS, as previously reported by Woo et al. and Woerd et al., [38, 39, 42]. A 5-point change in VHI-10 score is generally considered to represent clinically significant change in dysphonia associated handicap [45, 46]. In our study 68.1% of patients achieved the MCID for VHI-10 reduction during their follow up period, which is comparable to the results reported in Hirano et al’s 100-person VF bFGF injection study [13]. Our results support the hypothesis that PRP injections can provide phonatory benefit to patients with VF pathology affecting the lamina propria. We observed a consistent patient response trajectory of phonatory improvements reported from 2 to 4 weeks, with additional improvement over 3–6 months. Continued improvement of phonatory parameters over time supports PRP promoting a reparative and regenerative paradigm, rather than providing an immediate medialisation effect such as in traditional injection laryngoplasty [39, 47]. Furthermore, vocal fold appearances on videostroboscopy did not demonstrate persistent fullness as one might expect with bulking agent, and PRP was absorbed rapidly with return to pre-injection voice by the next day.

Given the wide range of subjective dysphonia measurement tools utilized in practice, we chose to measure a selection of different clinical phonatory outcomes in our follow up. Improvement in patient-reported scores matched improved objective measures and clinician-reported tools, suggesting that benefits in perceptual voice quality are evident to the listener, and coupled with improvements in vocal ease for the speaker during phonation. Patients consistently reported reduction in vocal fatigue and increased vocal consistency, regardless of initial vocal deficits which was confirmed by reduction in VFI scores over time. We hypothesise this to be on the basis of two physiological changes in the vocal fold. Firstly, the antifibrotic and inflammatory properties of PRP may be encouraging a physiological shift away from fibrotic processes, improving pliability of VF tissue [24, 28, 30]. Resulting improved propagation of mucosal wave, and reduction in the energy required to commence phonation (phonation threshold pressure) increases glottal contact time and reduces phonatory effort [48]. The changes to mucosal wave propagation seen in our stroboscopic data supports this hypothesis. Secondly, we suspect that the tissue regeneration properties of PRP stimulate some regenerative behaviour in an atrophic vocal fold where functional cells are present but dormant and require a stimulus to reinvigorate them. Stellate cells in the maculae flavae may provide such a pool and be induced to produce SLP elements that improve VF architecture, decreasing glottal insufficiency, and reducing energy expenditure imposed by air loss during phonation through incompletely closed VFs [14, 27, 49–51].

Limitations

The sample size, and heterogenous sample population are the main limitations of this study, reducing our ability to draw strong conclusions from subgroup analyses. Lack of blinding in rating stroboscopy could be addressed in future studies by using blinded external raters. Limitations in measurement tools may also introduce recall bias and expectation bias but by using a range of patient-based, clinician-based and objective measurements in our study we sought to limit this impact and enhance the strength of our conclusions [52]. In addition, we did not collect tissue specimens for analysis of structural components or molecular change in the VFs, and our PRP preparation technique did not included quantitation of platelet number in the supernatant.

Conclusions

PRP is an effective and feasible in-office treatment for benign pathology affecting the LP of the VF. Improvements in phonatory measurements following PRP injection were seen across a variety of voice disorders of varying severity (scar, sulcus, atrophy and inflammatory pathology). Improvements were maintained beyond 6 months and in some cases with only a single injection. Further research is needed to determine duration of effects beyond 6 months, and to ascertain which patient populations would benefit sufficiently from a single PRP injection compared to those who are likely to require serial injections.

Acknowledgements

We thank Linsell Richards Education Foundation for helping fund this project.

Funding

Open Access funding enabled and organized by CAUL and its Member Institutions

Declarations

Competing interests

The Authors have no conflict of interests to declare.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Hamilton NJI The life-cycle and restoration of the human vocal fold Laryngoscope Invest Otolaryngol 2022 8 1 168 176 10.1002/lio2.993
Hamilton NJI (2022) The life-cycle and restoration of the human vocal fold. Laryngoscope Invest Otolaryngol 8(1):168–176. 10.1002/lio2.993
2. de Melo ECM Lemos M Filho JAX Sennes LU Saldiva PHN Tsuji DH Distribution of collagen in the Lamina Propria of the Human Vocal fold Laryngoscope 2003 113 12 2187 2191 10.1097/00005537-200312000-00027 14660925
de Melo ECM, Lemos M, Filho JAX, Sennes LU, Saldiva PHN, Tsuji DH (2003) Distribution of collagen in the Lamina Propria of the Human Vocal fold. Laryngoscope 113(12):2187–2191. 10.1097/00005537-200312000-0002714660925
3. Gray SD Titze IR Chan R Hammond TH Vocal Fold proteoglycans and their influence on biomechanics Laryngoscope 1999 109 6 845 854 10.1097/00005537-199906000-00001 10369269
Gray SD, Titze IR, Chan R, Hammond TH (1999) Vocal Fold proteoglycans and their influence on biomechanics. Laryngoscope 109(6):845–854. 10.1097/00005537-199906000-0000110369269
4. Chan RW Gray SD Titze IR The importance of Hyaluronic Acid in Vocal fold Biomechanics Otolaryngol Head Neck Surg 2001 124 6 607 614 10.1177/019459980112400602 11391249
Chan RW, Gray SD, Titze IR (2001) The importance of Hyaluronic Acid in Vocal fold Biomechanics. Otolaryngol Head Neck Surg 124(6):607–614. 10.1177/01945998011240060211391249
5. Hirano S Minamiguchi S Yamashita M Ohno T Kanemaru S ichi, Kitamura M Histologic characterization of human scarred vocal folds J Voice 2009 23 4 399 407 10.1016/j.jvoice.2007.12.002 18395421
Hirano S, Minamiguchi S, Yamashita M, Ohno T, Kanemaru S, ichi, Kitamura M (2009) Histologic characterization of human scarred vocal folds. J Voice 23(4):399–407. 10.1016/j.jvoice.2007.12.00218395421
6. Friedrich G Dikkers FG Arens C Remacle M Hess M Giovanni A Vocal Fold scars: current concepts and future directions. Consensus report of the phonosurgery committee of the European laryngological society Eur Arch Oto-rhino-l 2013 270 9 2491 2507 10.1007/s00405-013-2498-9
Friedrich G, Dikkers FG, Arens C, Remacle M, Hess M, Giovanni A et al (2013) Vocal Fold scars: current concepts and future directions. Consensus report of the phonosurgery committee of the European laryngological society. Eur Arch Oto-rhino-l 270(9):2491–2507. 10.1007/s00405-013-2498-9
7. Peres A, de CS, Pessim ABB, Rodrigues SA, Martins RHG Effect of aging on the vocal muscle. J Voice. Published online 2022. 10.1016/j.jvoice.2022.03.020
8. Santos M, Freitas SV, Sousa CA, e, Silva ÁM (2023) da. Presbylarynx: validation of a classification based on morphological characteristics. Eur Arch Oto-rhino-l. ;280(2):781–788. 10.1007/s00405-022-07618-x
9. Santos M, Freitas SV, Sousa CA, e, Silva ÁM (2021) da. Presbylarynx: stratifying endoscopic signs for future researches. Eur Arch Oto-rhino-l. ;278(6):2157–2158. 10.1007/s00405-021-06735-3
10. Hantzakos A Dikkers FG Giovanni A Benninger MS Remacle M Sjögren EV Vocal Fold scars: a common classification proposal by the American Laryngological Association and European Laryngological Society Eur Arch Oto-rhino-l 2019 276 8 2289 2292 10.1007/s00405-019-05489-3
Hantzakos A, Dikkers FG, Giovanni A, Benninger MS, Remacle M, Sjögren EV et al (2019) Vocal Fold scars: a common classification proposal by the American Laryngological Association and European Laryngological Society. Eur Arch Oto-rhino-l 276(8):2289–2292. 10.1007/s00405-019-05489-3
11. Hsiung MW Woo P Wang HW Su WY A clinical classification and histopathological study of sulcus vocalis Eur Arch Oto-rhino-l 2000 257 8 466 468 10.1007/s004050000254
Hsiung MW, Woo P, Wang HW, Su WY (2000) A clinical classification and histopathological study of sulcus vocalis. Eur Arch Oto-rhino-l 257(8):466–468. 10.1007/s004050000254
12. Hirano S Kawamoto A Tateya I Mizuta M Kishimoto Y Hiwatashi N A phase I/II exploratory clinical trial for intracordal injection of recombinant hepatocyte growth factor for vocal Fold scar and sulcus J Tissue Eng Regen M 2018 12 4 1031 1038 10.1002/term.2603 29084372
Hirano S, Kawamoto A, Tateya I, Mizuta M, Kishimoto Y, Hiwatashi N et al (2018) A phase I/II exploratory clinical trial for intracordal injection of recombinant hepatocyte growth factor for vocal Fold scar and sulcus. J Tissue Eng Regen M 12(4):1031–1038. 10.1002/term.260329084372
13. Hirano S Sugiyama Y Kaneko M Mukudai S Fuse S Hashimoto K Intracordal Injection of Basic Fibroblast Growth factor in 100 cases of Vocal fold atrophy and scar Laryngoscope 2021 131 9 2059 2064 10.1002/lary.29200 33107605
Hirano S, Sugiyama Y, Kaneko M, Mukudai S, Fuse S, Hashimoto K (2021) Intracordal Injection of Basic Fibroblast Growth factor in 100 cases of Vocal fold atrophy and scar. Laryngoscope 131(9):2059–2064. 10.1002/lary.2920033107605
14. Heman-Ackah YD Ivey CM Alexander R Options for treatment of a small glottic gap Laryngoscope Investig Otolaryngol 2023 8 3 720 729 10.1002/lio2.1060 37342105
Heman-Ackah YD, Ivey CM, Alexander R (2023) Options for treatment of a small glottic gap. Laryngoscope Investig Otolaryngol 8(3):720–729. 10.1002/lio2.106037342105
15. Borzacchiello A Mayol L Ambrosio L Gärskog O Dahlqvist Å Rheological characterization of vocal folds after injection augmentation in a preliminary animal study J Bioact Compat Polym 2004 19 4 331 341 10.1177/0883911504045229
Borzacchiello A, Mayol L, Ambrosio L, Gärskog O, Dahlqvist Å (2004) Rheological characterization of vocal folds after injection augmentation in a preliminary animal study. J Bioact Compat Polym 19(4):331–341. 10.1177/0883911504045229
16. Echternach M Döllinger M Köberlein M Kuranova L Gellrich D Kainz MA Vocal Fold oscillation pattern changes related to loudness in patients with vocal Fold mass lesions J Otolaryngol - Head Neck Surg 2020 49 1 80 10.1186/s40463-020-00481-y 33228812
Echternach M, Döllinger M, Köberlein M, Kuranova L, Gellrich D, Kainz MA (2020) Vocal Fold oscillation pattern changes related to loudness in patients with vocal Fold mass lesions. J Otolaryngol - Head Neck Surg 49(1):80. 10.1186/s40463-020-00481-y33228812
17. Hertegård S Nagubothu SR Malmström E LeBlanc K Treatment of vocal Fold scarring with autologous bone marrow-derived human mesenchymal stromal cells—first phase I/II human clinical study Stem Cell Res Ther 2020 11 1 128 10.1186/s13287-020-01632-8 32197630
Hertegård S, Nagubothu SR, Malmström E, LeBlanc K (2020) Treatment of vocal Fold scarring with autologous bone marrow-derived human mesenchymal stromal cells—first phase I/II human clinical study. Stem Cell Res Ther 11(1):128. 10.1186/s13287-020-01632-832197630
18. Shiba TL Hardy J Luegmair G Zhang Z Long JL Tissue-Engineered Vocal fold mucosa implantation in rabbits Otolaryngol Head Neck Surg 2016 154 4 679 688 10.1177/0194599816628501 26956198
Shiba TL, Hardy J, Luegmair G, Zhang Z, Long JL (2016) Tissue-Engineered Vocal fold mucosa implantation in rabbits. Otolaryngol Head Neck Surg 154(4):679–688. 10.1177/019459981662850126956198
19. Mattei A Bertrand B Jouve E Blaise T Philandrianos C Grimaud F Feasibility of first injection of autologous adipose tissue–derived stromal vascular fraction in human scarred vocal folds Jama Otolaryngol Head Neck Surg 2020 146 4 355 363 10.1001/jamaoto.2019.4328 32053141
Mattei A, Bertrand B, Jouve E, Blaise T, Philandrianos C, Grimaud F et al (2020) Feasibility of first injection of autologous adipose tissue–derived stromal vascular fraction in human scarred vocal folds. Jama Otolaryngol Head Neck Surg 146(4):355–363. 10.1001/jamaoto.2019.432832053141
20. Cole BJ Karas V Hussey K Merkow DB Pilz K Fortier LA Hyaluronic Acid Versus platelet-rich plasma: a prospective, double-blind randomized controlled trial comparing clinical outcomes and effects on Intra-articular Biology for the treatment of knee osteoarthritis Am J Sports Med 2017 45 2 339 346 10.1177/0363546516665809 28146403
Cole BJ, Karas V, Hussey K, Merkow DB, Pilz K, Fortier LA (2017) Hyaluronic Acid Versus platelet-rich plasma: a prospective, double-blind randomized controlled trial comparing clinical outcomes and effects on Intra-articular Biology for the treatment of knee osteoarthritis. Am J Sports Med 45(2):339–346. 10.1177/036354651666580928146403
21. Huang Y Liu X Xu X Liu J Intra-articular injections of platelet-rich plasma, hyaluronic acid or corticosteroids for knee osteoarthritis Orthop 2019 48 3 239 247 10.1007/s00132-018-03659-5
Huang Y, Liu X, Xu X, Liu J (2019) Intra-articular injections of platelet-rich plasma, hyaluronic acid or corticosteroids for knee osteoarthritis. Orthop 48(3):239–247. 10.1007/s00132-018-03659-5
22. Martino AD Matteo BD Papio T Tentoni F Selleri F Cenacchi A Platelet-Rich plasma Versus Hyaluronic Acid injections for the treatment of knee osteoarthritis: results at 5 years of a Double-Blind, randomized controlled trial Am J Sports Med 2019 47 2 347 354 10.1177/0363546518814532 30545242
Martino AD, Matteo BD, Papio T, Tentoni F, Selleri F, Cenacchi A et al (2019) Platelet-Rich plasma Versus Hyaluronic Acid injections for the treatment of knee osteoarthritis: results at 5 years of a Double-Blind, randomized controlled trial. Am J Sports Med 47(2):347–354. 10.1177/036354651881453230545242
23. Xue X Bian Y Yang M Wei W Meng L Zhang Q Evaluation of injectable platelet-rich fibrin produced by a simple twice-centrifugation method combined with vacuum sealing drainage technology in the treatment of chronic refractory wounds Front Bioeng Biotechnol 2022 10 979834 10.3389/fbioe.2022.979834 36394016
Xue X, Bian Y, Yang M, Wei W, Meng L, Zhang Q et al (2022) Evaluation of injectable platelet-rich fibrin produced by a simple twice-centrifugation method combined with vacuum sealing drainage technology in the treatment of chronic refractory wounds. Front Bioeng Biotechnol 10:979834. 10.3389/fbioe.2022.97983436394016
24. Zhang Y Wang Z Zong C Gu X Fan S Xu L Platelet-rich plasma attenuates the severity of joint capsule fibrosis following post-traumatic joint contracture in rats Front Bioeng Biotechnol 2023 10 1078527 10.3389/fbioe.2022.1078527 36686225
Zhang Y, Wang Z, Zong C, Gu X, Fan S, Xu L et al (2023) Platelet-rich plasma attenuates the severity of joint capsule fibrosis following post-traumatic joint contracture in rats. Front Bioeng Biotechnol 10:1078527. 10.3389/fbioe.2022.107852736686225
25. Gato-Calvo L Hermida-Gómez T Romero CR Burguera EF Blanco FJ Anti-inflammatory effects of Novel standardized platelet Rich plasma releasates on knee osteoarthritic chondrocytes and cartilage in vitro Curr Pharm Biotechnol 2019 20 11 920 933 10.2174/1389201020666190619111118 31237204
Gato-Calvo L, Hermida-Gómez T, Romero CR, Burguera EF, Blanco FJ (2019) Anti-inflammatory effects of Novel standardized platelet Rich plasma releasates on knee osteoarthritic chondrocytes and cartilage in vitro. Curr Pharm Biotechnol 20(11):920–933. 10.2174/138920102066619061911111831237204
26. Yadav S Srivastava S Singh G Platelet-rich plasma exhibits anti‐inflammatory effect and attenuates cardiomyocyte damage by reducing NF‐κB and enhancing VEGF expression in isoproterenol induced cardiotoxicity model Environ Toxicol 2022 37 4 936 953 10.1002/tox.23456 35014750
Yadav S, Srivastava S, Singh G (2022) Platelet-rich plasma exhibits anti‐inflammatory effect and attenuates cardiomyocyte damage by reducing NF‐κB and enhancing VEGF expression in isoproterenol induced cardiotoxicity model. Environ Toxicol 37(4):936–953. 10.1002/tox.2345635014750
27. Xie X Zhang C Tuan RS Biology of platelet-rich plasma and its clinical application in cartilage repair Arthritis Res Ther 2014 16 1 204 10.1186/ar4493 25164150
Xie X, Zhang C, Tuan RS (2014) Biology of platelet-rich plasma and its clinical application in cartilage repair. Arthritis Res Ther 16(1):204. 10.1186/ar449325164150
28. Sassoli C Garella R Chellini F Tani A Pavan P Bambi F Platelet-rich plasma affects gap junctional features in myofibroblasts in vitro via vascular endothelial growth factor (VEGF)‐A/VEGF receptor Exp Physiol 2022 107 2 106 121 10.1113/ep090052 34935228
Sassoli C, Garella R, Chellini F, Tani A, Pavan P, Bambi F et al (2022) Platelet-rich plasma affects gap junctional features in myofibroblasts in vitro via vascular endothelial growth factor (VEGF)‐A/VEGF receptor. Exp Physiol 107(2):106–121. 10.1113/ep09005234935228
29. Bendinelli P Matteucci E Dogliotti G Corsi MM Banfi G Maroni P Molecular basis of anti-inflammatory action of platelet‐rich plasma on human chondrocytes: mechanisms of NF‐κB inhibition via HGF J Cell Physiol 2010 225 3 757 766 10.1002/jcp.22274 20568106
Bendinelli P, Matteucci E, Dogliotti G, Corsi MM, Banfi G, Maroni P et al (2010) Molecular basis of anti-inflammatory action of platelet‐rich plasma on human chondrocytes: mechanisms of NF‐κB inhibition via HGF. J Cell Physiol 225(3):757–766. 10.1002/jcp.2227420568106
30. Zhang J Middleton KK Fu FH Im HJ Wang JHC HGF mediates the anti-inflammatory effects of PRP on injured tendons PLoS ONE 2013 8 6 e67303 10.1371/journal.pone.0067303 23840657
Zhang J, Middleton KK, Fu FH, Im HJ, Wang JHC (2013) HGF mediates the anti-inflammatory effects of PRP on injured tendons. PLoS ONE 8(6):e67303. 10.1371/journal.pone.006730323840657
31. Woo SH Jeong HS Kim JP Koh EH Lee SU Jin SM Favorable vocal fold Wound Healing Induced by platelet-rich plasma injection Clin Exp Otorhinolar 2013 7 1 47 52 10.3342/ceo.2014.7.1.47
Woo SH, Jeong HS, Kim JP, Koh EH, Lee SU, Jin SM et al (2013) Favorable vocal fold Wound Healing Induced by platelet-rich plasma injection. Clin Exp Otorhinolar 7(1):47–52. 10.3342/ceo.2014.7.1.47
32. Dejnek M Witkowski J Moreira H Płaczkowska S Morasiewicz P Reichert P Content of blood cell components, inflammatory cytokines and growth factors in autologous platelet-rich plasma obtained by various methods World J Orthop 2022 13 6 587 602 10.5312/wjo.v13.i6.587 35949706
Dejnek M, Witkowski J, Moreira H, Płaczkowska S, Morasiewicz P, Reichert P et al (2022) Content of blood cell components, inflammatory cytokines and growth factors in autologous platelet-rich plasma obtained by various methods. World J Orthop 13(6):587–602. 10.5312/wjo.v13.i6.58735949706
33. Eppley BL, Woodell JE, Higgins J. Platelet Quantification and Growth Factor Analysis from Platelet-Rich Plasma Implications for Wound Healing. Plast Reconstr Surg. 2004;114(6):1502–1508. 10.1097/01.prs.0000138251.07040.51
34. DeLong JM Russell RP Mazzocca AD Platelet-Rich Plasma The PAW classification system Arthrosc J Arthrosc Relat Surg 2012 28 7 998 1009 10.1016/j.arthro.2012.04.148
DeLong JM, Russell RP, Mazzocca AD, Platelet-Rich, Plasma (2012) The PAW classification system. Arthrosc J Arthrosc Relat Surg 28(7):998–1009. 10.1016/j.arthro.2012.04.148
35. Tsou YA Tien VHC Chen SH Shih LC Lin TC Chiu CJ Autologous Fat Plus platelet-rich plasma versus autologous fat alone on Sulcus Vocalis J Clin Med 2022 11 3 725 10.3390/jcm11030725 35160180
Tsou YA, Tien VHC, Chen SH, Shih LC, Lin TC, Chiu CJ et al (2022) Autologous Fat Plus platelet-rich plasma versus autologous fat alone on Sulcus Vocalis. J Clin Med 11(3):725. 10.3390/jcm1103072535160180
36. Woo SH Kim JP Park JJ Chung PS Lee SH Jeong HS Autologous platelet-poor plasma gel for Injection Laryngoplasty Yonsei Med J 2013 54 6 1516 1523 10.3349/ymj.2013.54.6.1516 24142660
Woo SH, Kim JP, Park JJ, Chung PS, Lee SH, Jeong HS (2013) Autologous platelet-poor plasma gel for Injection Laryngoplasty. Yonsei Med J 54(6):1516–1523. 10.3349/ymj.2013.54.6.151624142660
37. Turkiye UUTF, Kulak Burun Bogaz Hastaliklari Anabilim Dali, Ankara, Ozgursoy SK, Tunckasik F, Tunckasik ME, Turkiye HSCDH Kulak Burun Bogaz Bolumu, Ankara, Akincioglu E et al (2018) Histopathologic Evaluation of Hyaluronic Acid and Plasma-Rich Platelet Injection into Rabbit Vocal Cords: An Experimental Study. Turk Otolarengoloji Arsivi Turkish Archives Otolaryngology. ;56(1):30–35. 10.5152/tao.2018.2942
38. Woerd B, O’Dell K, Castellanos CX, Bhatt N, Benssousan Y, Reddy NK et al Safety of Platelet-Rich Plasma Subepithelial Infusion for Vocal Fold Scar, Sulcus, and Atrophy. Laryngoscope. Published online 2022. 10.1002/lary.30288
39. Woo P Murry T Short-term Voice improvement after repeated Office-based platelet-rich plasma PRP injection in patients with vocal fold scar, Sulcus, and atrophy J Voice Published Online 2021 10.1016/j.jvoice.2021.02.022
Woo P, Murry T (2021) Short-term Voice improvement after repeated Office-based platelet-rich plasma PRP injection in patients with vocal fold scar, Sulcus, and atrophy. J Voice Published Online. 10.1016/j.jvoice.2021.02.022
40. Cobden SB Oztürk K Duman S Esen H Aktan TM Avunduk MC Treatment of Acute Vocal fold Injury with platelet-rich plasma J Voice 2016 30 6 731 735 10.1016/j.jvoice.2015.07.012 26292799
Cobden SB, Oztürk K, Duman S, Esen H, Aktan TM, Avunduk MC et al (2016) Treatment of Acute Vocal fold Injury with platelet-rich plasma. J Voice 30(6):731–735. 10.1016/j.jvoice.2015.07.01226292799
41. Gaafar A Eldeghiedy A ElMaghraby R Nouh I Donia M The role of platelet-rich plasma in microlaryngeal surgery: a randomised, controlled trial J Laryngology Otology 2022 136 8 737 741 10.1017/s0022215121004564
Gaafar A, Eldeghiedy A, ElMaghraby R, Nouh I, Donia M (2022) The role of platelet-rich plasma in microlaryngeal surgery: a randomised, controlled trial. J Laryngology Otology 136(8):737–741. 10.1017/s0022215121004564
42. Woo P Platelet-rich plasma in treatment of scar, atrophy, and sulcus: short‐ and long‐term results Laryngoscope Investig Otolaryngol Published Online 2023 10.1002/lio2.1143
Woo P (2023) Platelet-rich plasma in treatment of scar, atrophy, and sulcus: short‐ and long‐term results. Laryngoscope Investig Otolaryngol Published Online. 10.1002/lio2.1143
43. Medeiros N Castro MEM Lith-Bijl JT Desuter GRR A systematic review on Surgical treatments for Sulcus Vocalis and Vocal fold scar Laryngoscope 2022 132 4 822 830 10.1002/lary.29665 34057225
Medeiros N, Castro MEM, Lith-Bijl JT, Desuter GRR (2022) A systematic review on Surgical treatments for Sulcus Vocalis and Vocal fold scar. Laryngoscope 132(4):822–830. 10.1002/lary.2966534057225
44. Rosen CA Simpson CB Principles of Vocal fold Augmentation Operative techniques in Laryngology 2008 Berlin Heidelberg Springer 91 96
Rosen CA, Simpson CB (2008) Principles of Vocal fold Augmentation. Operative techniques in Laryngology. Springer-, Berlin Heidelberg, pp 91–96. doi:10.1007/978-3-540-68107-6_14
45. Gartner-Schmidt J Rosen C Treatment success for age‐related vocal Fold atrophy Laryngoscope 2011 121 3 585 589 10.1002/lary.21122 21344441
Gartner-Schmidt J, Rosen C (2011) Treatment success for age‐related vocal Fold atrophy. Laryngoscope 121(3):585–589. 10.1002/lary.2112221344441
46. Young VN Jeong K Rothenberger SD Gillespie AI Smith LJ Gartner-Schmidt JL Minimal clinically important difference of voice handicap index‐10 in vocal Fold paralysis Laryngoscope 2018 128 6 1419 1424 10.1002/lary.27001 29219184
Young VN, Jeong K, Rothenberger SD, Gillespie AI, Smith LJ, Gartner-Schmidt JL et al (2018) Minimal clinically important difference of voice handicap index‐10 in vocal Fold paralysis. Laryngoscope 128(6):1419–1424. 10.1002/lary.2700129219184
47. Henriques DP, Martins RHG, Cataneo AJM Efficacy of Injectable Laryngoplasty with Hyaluronic Acid and/or calcium hydroxyapatite in the Treatment of Glottic Incompetence. Systematic review and Meta-analysis. J Voice. Published online 2023. 10.1016/j.jvoice.2023.01.020
48. Chan RW Titze IR Dependence of phonation threshold pressure on vocal tract acoustics and vocal Fold tissue mechanics J Acoust Soc Am 2006 119 4 2351 2362 10.1121/1.2173516 16642848
Chan RW, Titze IR (2006) Dependence of phonation threshold pressure on vocal tract acoustics and vocal Fold tissue mechanics. J Acoust Soc Am 119(4):2351–2362. 10.1121/1.217351616642848
49. Sato K Hirano M Nakashima T 3D structure of the Macula Flava in the Human Vocal fold Acta Oto-laryngol 2003 123 2 269 273 10.1080/00016480310001123
Sato K, Hirano M, Nakashima T (2003) 3D structure of the Macula Flava in the Human Vocal fold. Acta Oto-laryngol 123(2):269–273. 10.1080/00016480310001123
50. Sato F Chitose S ichi, Sato K Kurita T Sato K Umeno H Differentiation potential of the cells in the macula flava of the human vocal fold mucosa Acta Histochem 2019 121 2 164 170 10.1016/j.acthis.2018.12.002 30558911
Sato F, Chitose S, ichi, Sato K, Kurita T, Sato K, Umeno H et al (2019) Differentiation potential of the cells in the macula flava of the human vocal fold mucosa. Acta Histochem 121(2):164–170. 10.1016/j.acthis.2018.12.00230558911
51. Sato K Umeno H Nakashima T Functional histology of the Macula Flava in the Human Vocal fold – part 1: its role in the Adult Vocal fold Folia Phoniatr Logo 2010 62 4 178 184 10.1159/000314261
Sato K, Umeno H, Nakashima T (2010) Functional histology of the Macula Flava in the Human Vocal fold – part 1: its role in the Adult Vocal fold. Folia Phoniatr Logo 62(4):178–184. 10.1159/000314261
52. Dejonckere PH Bradley P Clemente P Cornut G Crevier-Buchman L Friedrich G A basic protocol for functional assessment of voice pathology, especially for investigating the efficacy of (phonosurgical) treatments and evaluating new assessment techniques Eur Arch Oto-rhino-l 2001 258 2 77 82 10.1007/s004050000299
Dejonckere PH, Bradley P, Clemente P, Cornut G, Crevier-Buchman L, Friedrich G et al (2001) A basic protocol for functional assessment of voice pathology, especially for investigating the efficacy of (phonosurgical) treatments and evaluating new assessment techniques. Eur Arch Oto-rhino-l 258(2):77–82. 10.1007/s004050000299
